

# Philip Korthuis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/266043/publications.pdf>

Version: 2024-02-01

177  
papers

8,679  
citations

57758

44  
h-index

51608

86  
g-index

178  
all docs

178  
docs citations

178  
times ranked

10845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stigma as a barrier to integrated substance use and HIV care in Vietnam: A qualitative examination of patient and provider perspectives. <i>Journal of Ethnicity in Substance Abuse</i> , 2024, 23, 182-197.	0.9	0
2	The process and challenges of language translation and cultural adaptation of study instruments: a case study from the NIDA CTN CHOICES-2 trial. <i>Journal of Ethnicity in Substance Abuse</i> , 2023, 22, 417-432.	0.9	3
3	Contraception and Healthcare Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities: a Cross-Sectional Survey. <i>Journal of General Internal Medicine</i> , 2023, 38, 98-106.	2.6	2
4	Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. <i>Pain</i> , 2022, 163, 83-90.	4.2	33
5	Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2022, 134, 108451.	2.8	5
6	Exploring how Hospitalization Can Alter Hepatitis C Virus Treatment Prioritization and Trajectories in People who Use Drugs: A Qualitative Analysis. <i>Substance Abuse</i> , 2022, 43, 245-252.	2.3	1
7	Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108615.	2.8	5
8	Causes of Death in the 12 Months After Hospital Discharge Among Patients With Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2022, 16, 466-469.	2.6	13
9	Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study. <i>Journal of Behavioral Health Services and Research</i> , 2022, 49, 240-251.	1.4	2
10	Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. <i>AIDS and Behavior</i> , 2022, 26, 975-985.	2.7	8
11	Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108509.	2.8	1
12	COVID-19-Related Policy Changes for Methadone Take-Home Dosing: A Multistate Survey of Opioid Treatment Program Leadership. <i>Substance Abuse</i> , 2022, 43, 633-639.	2.3	23
13	Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam. <i>International Journal of Drug Policy</i> , 2022, 100, 103503.	3.3	0
14	Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality. <i>International Journal of Drug Policy</i> , 2022, 100, 103525.	3.3	3
15	Evaluation of a Medicaid performance improvement project to reduce high-dose opioid prescriptions. <i>BMC Health Services Research</i> , 2022, 22, 68.	2.2	0
16	HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. <i>Addiction</i> , 2022, 117, 1961-1971.	3.3	10
17	Familial Support in Integrated Treatment with Antiretroviral Therapy and Medications for Opioid use Disorder in Vietnam: A Qualitative Study. <i>Substance Abuse</i> , 2022, 43, 1004-1010.	2.3	2
18	Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 141, 108801.	2.8	26

#	ARTICLE	IF	CITATIONS
19	A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews. Journal of General Internal Medicine, 2022, 37, 2821-2833.	2.6	39
20	COVID-19 Vaccination Status and Concerns Among People Who Use Drugs in Oregon. Journal of Addiction Medicine, 2022, 16, 695-701.	2.6	3
21	"It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply. Harm Reduction Journal, 2022, 19, .	3.2	7
22	Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapy. Pharmacoepidemiology and Drug Safety, 2021, 30, 395-399.	1.9	5
23	Provider Perspectives on Integration of Substance Use Disorder and HIV Care in Vietnam: A Qualitative Study. Journal of Behavioral Health Services and Research, 2021, 48, 274-286.	1.4	5
24	Harm Reduction and Adaptations Among PWUD in Rural Oregon During COVID-19. AIDS and Behavior, 2021, 25, 1331-1339.	2.7	21
25	HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. Lancet HIV, 2021, 8, e67-e76.	4.7	17
26	Drug and Alcohol Dependence response to KK-21-1460 "Considering rationales for use in defining subgroups for the treatment of stimulant use disorder". Drug and Alcohol Dependence, 2021, 221, 108571.	3.2	0
27	Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. International Journal of Drug Policy, 2021, 96, 103356.	3.3	2
28	"Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. Journal of Substance Abuse Treatment, 2021, 127, 108337.	2.8	6
29	Designing and validating a Markov model for hospital-based addiction consult service impact on 12-month drug and non-drug related mortality. PLoS ONE, 2021, 16, e0256793.	2.5	7
30	Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study. BMC Public Health, 2021, 21, 1718.	2.9	4
31	Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study. Drug and Alcohol Dependence, 2021, 227, 108912.	3.2	11
32	Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. Drug and Alcohol Dependence, 2021, 228, 108923.	3.2	17
33	Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. Drug and Alcohol Dependence, 2021, 228, 109077.	3.2	10
34	"Like Yin and Yang": Perceptions of Methamphetamine Benefits and Consequences Among People Who Use Opioids in Rural Communities. Journal of Addiction Medicine, 2021, 15, 34-39.	2.6	35
35	Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation. Journal of Addiction Medicine, 2021, 15, 130-133.	2.6	3
36	Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review. Journal of Addiction Medicine, 2021, 15, 74-84.	2.6	27

#	ARTICLE	IF	CITATIONS
37	Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 67.	2.6	3
38	Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 72.	2.6	26
39	A cross-sectional survey of potential factors, motivations, and barriers influencing research participation and retention among people who use drugs in the rural USA. <i>Trials</i> , 2021, 22, 948.	1.6	5
40	Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. <i>Journal of Substance Abuse Treatment</i> , 2020, 109, 14-22.	2.8	16
41	Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study. <i>Journal of General Internal Medicine</i> , 2020, 35, 3188-3196.	2.6	11
42	A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108193.	3.2	36
43	HIV care continuum characteristics among people with opioid use disorder and HIV in Vietnam: baseline results from the BRAVO study. <i>BMC Public Health</i> , 2020, 20, 421.	2.9	8
44	Are clinicians's self-reported empathic concern and perspective-taking traits associated with their response to patient emotions?. <i>Patient Education and Counseling</i> , 2020, 103, 1745-1751.	2.2	6
45	Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. <i>Health and Justice</i> , 2020, 8, 18.	2.1	15
46	Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service. <i>Journal of Addiction Medicine</i> , 2020, 14, 415-422.	2.6	39
47	Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108272.	3.2	8
48	Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: A latent transition analysis. <i>Journal of Substance Abuse Treatment</i> , 2020, 118, 108121.	2.8	28
49	Racial disparities in clinician responses to patient emotions. <i>Patient Education and Counseling</i> , 2020, 103, 1736-1744.	2.2	19
50	Addressing Missing Data in Substance Use Research: A Review and Data Justice-based Approach. <i>Journal of Addiction Medicine</i> , 2020, 14, 454-456.	2.6	10
51	Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018. <i>PLoS ONE</i> , 2020, 15, e0242165.	2.5	40
52	Title is missing!. , 2020, 15, e0242165.		0
53	Title is missing!. , 2020, 15, e0242165.		0
54	Title is missing!. , 2020, 15, e0242165.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0242165.		0
56	Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. Lancet HIV,the, 2019, 6, e531-e539.	4.7	18
57	Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. Journal of General Internal Medicine, 2019, 34, 2796-2803.	2.6	132
58	Effects of Naltrexone on Large-Scale Network Interactions in Methamphetamine Use Disorder. Frontiers in Psychiatry, 2019, 10, 603.	2.6	13
59	Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports, 2019, 16, 1-6.	3.1	48
60	Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. Journal of Substance Abuse Treatment, 2019, 103, 23-32.	2.8	16
61	Preexposure Prophylaxis for the Prevention of HIV Infection. JAMA - Journal of the American Medical Association, 2019, 321, 2214.	7.4	172
62	Emotional Communication in HIV Care: An Observational Study of Patients's™ Expressed Emotions and Clinician Response. AIDS and Behavior, 2019, 23, 2816-2828.	2.7	11
63	Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug and Alcohol Dependence, 2019, 198, 70-75.	3.2	29
64	Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018. JAMA - Journal of the American Medical Association, 2019, 321, 607.	7.4	26
65	Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Annals of Internal Medicine, 2019, 170, 509.	3.9	2
66	Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Services Research, 2019, 19, 862.	2.2	26
67	Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the <sc>HIV</sc> Research Network. HIV Medicine, 2019, 20, 169-174.	2.2	9
68	Use of single IRBs for multi-site studies: A case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. Contemporary Clinical Trials Communications, 2019, 14, 100319.	1.1	12
69	Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annual Review of Public Health, 2018, 39, 525-541.	17.4	57
70	A statewide effort to reduce high-dose opioid prescribing through coordinated care organizations. Addictive Behaviors, 2018, 86, 32-39.	3.0	6
71	The SUMMIT ambulatory-ICU primary care model for medically and socially complex patients in an urban federally qualified health center: study design and rationale. Addiction Science & Clinical Practice, 2018, 13, 27.	2.6	12
72	A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug and Alcohol Dependence, 2018, 192, 186-192.	3.2	22

#	ARTICLE	IF	CITATIONS
73	Racial/ethnic differences in the association between alcohol use and mortality among men living with HIV. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 2.	2.6	11
74	Substance use and the HIV care continuum: important advances. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 13.	2.6	27
75	Lessons Learned from the Implementation of a Medically Enhanced Residential Treatment (MERT) Model Integrating Intravenous Antibiotics and Residential Addiction Treatment. <i>Substance Abuse</i> , 2018, 39, 225-232.	2.3	23
76	Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. <i>Current HIV/AIDS Reports</i> , 2018, 15, 315-323.	3.1	25
77	Three integrated elements of empowerment: HIV prevention with sub-Saharan African adolescent females involved in transactional sex.. <i>Clinical Practice in Pediatric Psychology</i> , 2018, 6, 355-363.	0.3	3
78	Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. <i>Annals of Internal Medicine</i> , 2018, 169, 335-336.	3.9	53
79	Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. <i>Addiction</i> , 2017, 112, 1036-1044.	3.3	51
80	“It’s been an Experience, a Life Learning Experience” A Qualitative Study of Hospitalized Patients with Substance Use Disorders. <i>Journal of General Internal Medicine</i> , 2017, 32, 296-303.	2.6	109
81	Primary Care-Based Models for the Treatment of Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2017, 166, 268.	3.9	224
82	How does decision complexity affect shared decision making? An analysis of patient-provider antiretroviral initiation dialogue. <i>Patient Education and Counseling</i> , 2017, 100, 919-926.	2.2	4
83	Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004–2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 409-416.	2.1	18
84	Integrase strand transfer inhibitor-associated diabetes mellitus: A case report. <i>International Journal of STD and AIDS</i> , 2017, 28, 626-628.	1.1	37
85	Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings. <i>Annals of Internal Medicine</i> , 2017, 167, 867.	3.9	51
86	Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder. <i>Journal of Hospital Medicine</i> , 2017, 12, 339-342.	1.4	123
87	Buprenorphine+Naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. <i>Addiction</i> , 2016, 111, 1416-1427.	3.3	53
88	Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures?. <i>Journal of General Internal Medicine</i> , 2016, 31, 1141-1147.	2.6	7
89	A Delayed Injection-Site Reaction in a Patient Receiving Extended-Release Naltrexone. <i>Substance Abuse</i> , 2016, 37, 278-280.	2.3	4
90	HIV Patients' Preference for Integrated Models of Addiction and HIV Treatment in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2016, 69, 57-63.	2.8	15

#	ARTICLE	IF	CITATIONS
91	Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients?. <i>AIDS and Behavior</i> , 2016, 20, 1108-1115.	2.7	10
92	Healthcare Coverage for HIV Provider Visits Before and After Implementation of the Affordable Care Act. <i>Clinical Infectious Diseases</i> , 2016, 63, 387-395.	5.8	20
93	Clinician empathy is associated with differences in patientâ€“clinician communication behaviors and higher medication self-efficacy in HIV care. <i>Patient Education and Counseling</i> , 2016, 99, 220-226.	2.2	89
94	Quality of HIV Care and Mortality Rates in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2016, 62, 233-239.	5.8	22
95	Respecting patients is associated with more patient-centered communication behaviors in clinical encounters. <i>Patient Education and Counseling</i> , 2016, 99, 250-255.	2.2	33
96	Cumulative Incidence of Cancer Among Persons With HIV in North America. <i>Annals of Internal Medicine</i> , 2015, 163, 507-518.	3.9	271
97	Factors associated with willingness to take extended release naltrexone among injection drug users. <i>Addiction Science &amp; Clinical Practice</i> , 2015, 10, 12.	2.6	27
98	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 275-279.	2.1	17
99	A mixed methods study of patientâ€“provider communication about opioid analgesics. <i>Patient Education and Counseling</i> , 2015, 98, 453-461.	2.2	33
100	Impact of a brief patient and provider intervention to improve the quality of communication about medication adherence among HIV patients. <i>Patient Education and Counseling</i> , 2015, 98, 1078-1083.	2.2	49
101	Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 1692-1702.	4.0	105
102	Hepatitis C Virus Testing in Adults Living with HIV: A Need for Improved Screening Efforts. <i>PLoS ONE</i> , 2014, 9, e102766.	2.5	16
103	Authors' Reply. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e142-e143.	2.1	0
104	Trends in Hospitalizations Among Children and Young Adults with Perinatally Acquired HIV. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 488-494.	2.0	17
105	HIV Risk Reduction With Buprenorphineâ€“Naloxone or Methadone. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 288-293.	2.1	77
106	Does This Adult Patient Have Early HIV Infection?. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 278.	7.4	26
107	Providerâ€“Patient Communication About Adherence to Anti-retroviral Regimens Differs by Patient Race and Ethnicity. <i>AIDS and Behavior</i> , 2014, 18, 1279-1287.	2.7	22
108	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014, 50, 1169-1176.	1.5	77



#	ARTICLE	IF	CITATIONS
109	Retention in Care Is More Strongly Associated With Viral Suppression in HIV-Infected Patients With Lower Versus Higher CD4 Counts. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 333-339.	2.1	63
110	Primary Care Provider Cultural Competence and Racial Disparities in HIV Care and Outcomes. <i>Journal of General Internal Medicine</i> , 2013, 28, 622-629.	2.6	79
111	Patient Activation and Improved Outcomes in HIV-Infected Patients. <i>Journal of General Internal Medicine</i> , 2013, 28, 668-674.	2.6	90
112	Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1701.	7.4	111
113	Counseling to Reduce High-Risk Sexual Behavior in HIV Care: A Multi-Center, Direct Observation Study. <i>AIDS Patient Care and STDs</i> , 2013, 27, 416-424.	2.5	17
114	The impact of depressive symptoms on patientâ€™provider communication in HIV care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 1185-1192.	1.2	16
115	Provider-patient Adherence Dialogue in HIV Care: Results of a Multisite Study. <i>AIDS and Behavior</i> , 2013, 17, 148-159.	2.7	40
116	Motivational interviewing by HIV care providers is associated with patient intentions to reduce unsafe sexual behavior. <i>Patient Education and Counseling</i> , 2013, 93, 122-129.	2.2	15
117	HIV rapid testing in drug treatment: comparison across treatment modalities. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 369-374.	2.8	10
118	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001â€“2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	5.8	90
119	Race, Relationships, and Trust in Providers among Black Patients with HIV/AIDS. <i>Social Work Research</i> , 2013, 37, 219-226.	0.6	43
120	Changes in Advanced Immunosuppression and Detectable HIV Viremia Among Perinatally HIV-Infected Youth in the Multisite United States HIV Research Network. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 215-223.	1.3	24
121	A Multicenter Study of Physician Mindfulness and Health Care Quality. <i>Annals of Family Medicine</i> , 2013, 11, 421-428.	1.9	186
122	Conformity of Pediatric/Adolescent HIV Clinics to the Patient-Centered Medical Home Care Model. <i>AIDS Patient Care and STDs</i> , 2013, 27, 272-279.	2.5	13
123	Correlates of HIV Risk Behaviors among Homeless and Unstably Housed Young Adults. <i>Public Health Reports</i> , 2013, 128, 153-160.	2.5	17
124	Thirty-day hospital readmission rate among adults living with HIV. <i>Aids</i> , 2013, 27, 2059-2068.	2.2	27
125	Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001â€“2009. <i>PLoS ONE</i> , 2013, 8, e78952.	2.5	9
126	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. <i>PLoS ONE</i> , 2013, 8, e81355.	2.5	1,111



#	ARTICLE	IF	CITATIONS
127	Patient and provider comfort discussing substance use. <i>Family Medicine</i> , 2013, 45, 109-17.	0.5	20
128	HIV Providers' Perceptions of and Attitudes Toward Female Versus Male Patients. <i>AIDS Patient Care and STDs</i> , 2012, 26, 582-588.	2.5	14
129	Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 249-259.	2.1	144
130	Comparing different measures of retention in outpatient HIV care. <i>Aids</i> , 2012, 26, 1131-1139.	2.2	101
131	Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. <i>American Journal of Public Health</i> , 2012, 102, 1160-1167.	2.7	86
132	Unhealthy Alcohol and Illicit Drug Use Are Associated With Decreased Quality of HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 171-178.	2.1	51
133	Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness. <i>Addictive Behaviors</i> , 2012, 37, 552-555.	3.0	17
134	Predictors of Highly Active Antiretroviral Therapy Utilization for Behaviorally HIV-1â€“Infected Youth: Impact of Adult Versus Pediatric Clinical Care Site. <i>Journal of Adolescent Health</i> , 2012, 50, 471-477.	2.5	26
135	Providing support to patients in emotional encounters: A new perspective on missed empathic opportunities. <i>Patient Education and Counseling</i> , 2012, 88, 436-442.	2.2	42
136	Clinician Stress and Patientâ€“Clinician Communication in HIV Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 1635-1642.	2.6	13
137	Screening for HIV: Systematic Review to Update the 2005 U.S. Preventive Services Task Force Recommendation. <i>Annals of Internal Medicine</i> , 2012, 157, 706.	3.9	32
138	Factors Affecting Clinician Educator Encouragement of Routine HIV Testing Among Trainees. <i>Journal of General Internal Medicine</i> , 2012, 27, 839-844.	2.6	19
139	NIDAâ€™s Clinical Trials Network: An Opportunity for HIV Research in Community Substance Abuse Treatment Programs. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 283-293.	2.1	5
140	The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, S76-S82.	2.1	18
141	Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, S83-S90.	2.1	45
142	Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, S39-S45.	2.1	60
143	Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000â€“2005. <i>Aids</i> , 2011, 25, 717-720.	2.2	14
144	Pregnancy Incidence and Outcomes in Vertically and Behaviorally HIV-Infected Youth. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 468.	7.4	31

#	ARTICLE	IF	CITATIONS
145	The role of cultural distance between patient and provider in explaining racial/ethnic disparities in HIV care. Patient Education and Counseling, 2011, 85, e278-e284.	2.2	47
146	Patientâ€“Provider Communication Differs for Black Compared to White HIV-Infected Patients. AIDS and Behavior, 2011, 15, 805-811.	2.7	98
147	Substance Use and the Quality of Patient-Provider Communication in HIV Clinics. AIDS and Behavior, 2011, 15, 832-841.	2.7	36
148	Provider and Practice Characteristics Associated with Use of Rapid HIV Testing by General Internists. Journal of General Internal Medicine, 2011, 26, 1258-64.	2.6	6
149	Internet Health Information Seeking Behavior and Antiretroviral Adherence in Persons Living with HIV/AIDS. AIDS Patient Care and STDs, 2011, 25, 445-449.	2.5	68
150	The Source of Methadone in Overdose Deaths in Western Virginia in 2004. Journal of Addiction Medicine, 2011, 5, 188-202.	2.6	41
151	HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, S22-S32.	2.1	223
152	Disparities in Antiretroviral Treatment: A Comparison of Behaviorally HIV-Infected Youth and Adults in the HIV Research Network. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 100-107.	2.1	29
153	General Internists' Beliefs, Behaviors, and Perceived Barriers to Routine HIV Screening in Primary Care. AIDS Education and Prevention, 2011, 23, 70-83.	1.1	50
154	Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. American Journal of Managed Care, 2011, 17 Suppl 8, S222-34.	1.1	13
155	Patients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care. Journal of Addiction Medicine, 2010, 4, 204-210.	2.6	56
156	â€œWeâ€™ll Do this Togetherâ€“ The Role of the First Person Plural in Fostering Partnership in Patient-physician Relationships. Journal of General Internal Medicine, 2010, 25, 186-193.	2.6	15
157	Decision-Making Role Preferences Among Patients with HIV: Associations with Patient and Provider Characteristics and Communication Behaviors. Journal of General Internal Medicine, 2010, 25, 517-523.	2.6	30
158	Differences in Patientâ€“Provider Communication for Hispanic Compared to Non-Hispanic White Patients in HIV Care. Journal of General Internal Medicine, 2010, 25, 682-687.	2.6	78
159	Emergency department utilization among HIVâ€“infected patients in a multisite multistate study<sup>*</sup>. HIV Medicine, 2010, 11, 74-84.	2.2	35
160	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	12.6	1,054
161	Use of outpatient mental health services and psychotropic medications among HIV-infected patients in a multisite, multistate study. General Hospital Psychiatry, 2009, 31, 538-545.	2.4	19
162	The Impact of Integrated HIV Care on Patient Health Outcomes. Medical Care, 2009, 47, 560-567.	2.4	59

#	ARTICLE	IF	CITATIONS
163	Impact of Patient Race on Patient Experiences of Access and Communication in HIV Care. Journal of General Internal Medicine, 2008, 23, 2046-2052.	2.6	14
164	Alcohol use among HIV-infected persons in care: results of a multi-site survey <sup>*</sup> . HIV Medicine, 2008, 9, 196-202.	2.2	82
165	Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions. Journal of Substance Abuse Treatment, 2008, 35, 294-303.	2.8	37
166	Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance Use. AIDS Patient Care and STDs, 2008, 22, 859-867.	2.5	90
167	Structures of Care in the Clinics of the HIV Research Network. AIDS Patient Care and STDs, 2008, 22, 1007-1013.	2.5	43
168	The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 1134-1140.	1.2	65
169	Associations between Outpatient and Inpatient Service Use among Persons with HIV Infection: A Positive or Negative Relationship?. Health Services Research, 2007, 43, 76-95.	2.0	19
170	Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet, The, 2006, 368, 1503-1515.	13.7	92
171	Hospital and Outpatient Health Services Utilization Among HIV-Infected Adults in Care 2000-2002. Medical Care, 2005, 43, III-40.	2.4	137
172	Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 96-103.	2.1	252
173	Prenatal Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2005, 143, 38.	3.9	54
174	Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2005, 143, 55.	3.9	114
175	Lipid Screening in HIV-Infected Veterans. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 253-260.	2.1	10
176	Measuring Medication. Medical Care, 2002, 40, 1270-1282.	2.4	23
177	Implementation of a cross-cultural evidence-based medicine curriculum. Medical Teacher, 2002, 24, 444-446.	1.8	5